Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB (publ) (“NextCell” or the “Company”) today announces the 12-month results from ProTrans-Young. In the predefined age group of 7–11 years, children treated with NXTCL-T1D had, on average, preserved a greater proportion of their endogenous insulin production after 12 months and experienced a smaller increase in insulin requirements compared with those receiving placebo. The study did not meet its primary efficacy endpoint in the overall study population. A preliminary analysis of 24-month data from the older age group shows no clear treatment effect, although the data have not yet been fully analysed or validated. NextCell’s commercialisation strategy for adults remains unchanged, while the Company intends to refine its treatment strategy for children and adolescents, focusing on treatment timing and the number of administrations. Further analyses are also planned to investigate how age and individual disease progression may influence treatment response.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) announces that topline results from the ProTrans-Young clinical trial have not yet been reported to the company. The extended timeline is due to the final administrative processing and sign-off of study data taking longer than planned and is not related to the outcome of the study. The data are now being handled by statisticians at Uppsala Clinical Research Center (UCR).

NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell’s clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the second quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

NextCell Pharma AB ("NextCell" or the "Company") has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. In parallel, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), effective 1 September. NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026, held 9–12 September.

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Interim report for the first quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year.  Please note that, as of 2025, the Company’s financial year corresponds to the calendar year.

On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 (“NextCell” or the “Company”), was held. A summary of the resolutions adopted at the Annual General Meeting is set out below. All resolutions were adopted with the required majority. For more detailed information regarding the content of the resolutions, reference is made to the notice convening the Annual General Meeting and the complete proposals for resolutions, which have previously been published and are available on the Company’s website, www.nextcellpharma.com.

NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.